Beyond Air Inc
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treat… Read more
Beyond Air Inc (XAIR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.509x
Based on the latest financial reports, Beyond Air Inc (XAIR) has a cash flow conversion efficiency ratio of -0.509x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.22 Million) by net assets ($8.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beyond Air Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Beyond Air Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beyond Air Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beyond Air Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
-0.092x |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
-1.143x |
|
Xbrane Biopharma AB
ST:XBRANE
|
-0.121x |
|
SynCore Biotechnology Co Ltd
TWO:4192
|
-0.028x |
|
Iconic Worldwide Bhd
KLSE:9113
|
-0.018x |
|
Turnium Technology Group Inc.
V:TTGI
|
0.073x |
|
Nam Sung
KO:004270
|
-0.041x |
|
KRONA PUBLIC REAL ESTATE
F:927
|
N/A |
Annual Cash Flow Conversion Efficiency for Beyond Air Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Beyond Air Inc from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $14.34 Million | $-38.22 Million | -2.665x | -29.34% |
| 2024-03-31 | $27.19 Million | $-56.02 Million | -2.060x | -162.34% |
| 2023-03-31 | $42.03 Million | $-33.01 Million | -0.785x | -165.52% |
| 2022-03-31 | $78.21 Million | $-23.13 Million | -0.296x | +54.12% |
| 2021-03-31 | $30.46 Million | $-19.64 Million | -0.645x | +23.23% |
| 2020-03-31 | $18.09 Million | $-15.19 Million | -0.840x | -352.02% |
| 2019-03-31 | $4.02 Million | $1.34 Million | 0.333x | +107.23% |
| 2018-03-31 | $1.54 Million | $-7.12 Million | -4.610x | -116.76% |
| 2017-03-31 | $-25.16K | $-692.00K | 27.504x | -58.26% |
| 2016-03-31 | $-25.16K | $-1.66 Million | 65.898x | +3679.61% |
| 2015-03-31 | $-1.08 Million | $-1.88 Million | 1.744x | -49.69% |
| 2014-03-31 | $-232.00K | $-804.00K | 3.466x | -- |